Mirae Asset Global Investments Co. Ltd. Has $3.90 Million Stock Position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Mirae Asset Global Investments Co. Ltd. reduced its holdings in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 15.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 130,858 shares of the medical device company’s stock after selling 23,457 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Tandem Diabetes Care were worth $3,896,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the business. RiverPark Advisors LLC acquired a new stake in shares of Tandem Diabetes Care in the fourth quarter worth $27,000. State of Wyoming boosted its holdings in Tandem Diabetes Care by 45.8% in the 4th quarter. State of Wyoming now owns 821 shares of the medical device company’s stock valued at $37,000 after purchasing an additional 258 shares during the period. PNC Financial Services Group Inc. grew its position in Tandem Diabetes Care by 51.7% in the 3rd quarter. PNC Financial Services Group Inc. now owns 3,226 shares of the medical device company’s stock worth $67,000 after purchasing an additional 1,099 shares during the last quarter. Stephens Inc. AR increased its holdings in shares of Tandem Diabetes Care by 17.6% during the 1st quarter. Stephens Inc. AR now owns 2,120 shares of the medical device company’s stock worth $86,000 after purchasing an additional 317 shares during the period. Finally, Jefferies Financial Group Inc. acquired a new position in shares of Tandem Diabetes Care during the fourth quarter valued at about $89,000.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on TNDM shares. Citigroup lifted their target price on Tandem Diabetes Care from $31.00 to $38.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 3rd. Stifel Nicolaus raised Tandem Diabetes Care from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $24.00 to $37.00 in a report on Tuesday, March 26th. Finally, StockNews.com cut Tandem Diabetes Care from a “hold” rating to a “sell” rating in a research report on Thursday, April 11th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $37.00.

Tandem Diabetes Care Trading Up 3.5 %

Shares of TNDM opened at $32.96 on Wednesday. The company has a current ratio of 3.83, a quick ratio of 3.02 and a debt-to-equity ratio of 0.91. The stock has a market cap of $2.13 billion, a PE ratio of -9.58 and a beta of 1.11. Tandem Diabetes Care, Inc. has a 1 year low of $13.82 and a 1 year high of $42.09. The stock has a 50 day simple moving average of $29.30 and a 200-day simple moving average of $24.62.

Tandem Diabetes Care (NASDAQ:TNDM) last announced its quarterly earnings results on Wednesday, February 21st. The medical device company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). The company had revenue of $196.80 million during the quarter, compared to the consensus estimate of $204.86 million. Tandem Diabetes Care had a negative net margin of 29.77% and a negative return on equity of 31.48%. On average, sell-side analysts predict that Tandem Diabetes Care, Inc. will post -1.62 EPS for the current fiscal year.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.